Published in Obesity and Diabetes Week, February 2nd, 2004
The Swissmedic indicated that they require additional clinical information to demonstrate the benefits of Symlin therapy relative to risks associated with adverse events, including nausea and hypoglycemia. Amylin submitted the original application in August 2001, and in March 2003 submitted a response to the original inquiries from the Swissmedic, which included an interim analysis of a Symlin dose-titration study. The Swiss regulatory...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.